Hipertrofia pilorica. 1. Hipertrofia pilórica ROCIO MORENO ALVARADO; 2. SÍNDROME PILÓRICO CARACTERIZA DO POR LA OBSTRUCCIÓ. HIPERTROFIA PROSTATICA BENIGNA HPB – BPH DOCTOR ALEJANDRO SEGEBRE – Duration: Dr. Alejandro Segebre , views. Hipertrofia pilorica Mis casitos radiológicos CD added 7 new photos. July 4 ·. Hipertrofia pilorica Image may contain: text · No automatic alt text available.

Author: Ninos Dami
Country: South Sudan
Language: English (Spanish)
Genre: Sex
Published (Last): 20 November 2010
Pages: 100
PDF File Size: 4.95 Mb
ePub File Size: 15.39 Mb
ISBN: 878-4-70274-643-7
Downloads: 49907
Price: Free* [*Free Regsitration Required]
Uploader: Taugami

Clinical trials

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name. Pneumonia AND sponsor name.

How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field.

Trials with results Trials without results Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned.


EU Clinical Trials Register. Both Female Only Male Only.

Quiste de duplicación gástrico: diagnóstico por punción-aspiración guiada por ecoendoscopia

IMP with orphan designation in the indication. Trials with results Trials without results. Clear advanced search filters.

Date on which this record was first entered in the EudraCT database:.

Clinical Trials Register

Title of the trial for lay people, in easily understood, i. The IMP has been designated in this indication as an orphan drug pilorifa the Community.

Committee on Advanced therapies CAT has issued a classification for this product. Combination product that includes a device, but does not involve an Advanced Therapy.

Objetivos Principales del Subestudio: Se permite el tratamiento antitrombotico con dosis bajas de aspirina. The trial involves single site in the Member State concerned. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.

Plans for treatment hipertrofiaa care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.